FDA Grants Accelerated Approval for New Head and Neck Cancer Therapy

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro). This dual-targeted therapy is approved for adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after platinum-based chemotherapy and anti–PD-1/PD-L1 antibody treatment. This marks the first dual-targeted therapy for this specific indication, offering a new treatment option.